PDCD1 and hepatocellular carcinoma: Tislelizumab is a humanized antibody against PD-1 that was approved for HCC by the China National Medical Products Administration (NMPA) based on the results of the randomized phase II/III clinical trial RATIONALE-301 (NCT03412773).